

Pharmaceutical pricing and access to medicines 25th April 2019

CONDITIONS FOR USE OF TRANSCRIPTS:

This document is intended to provide a timely reference for interested parties who are unable to attend the event to which it refers. Some portions are based on transcripts of proceedings and others consist of text submitted by speakers or authors, and are clearly marked as such. As such, apart from where it is indicated that the text was supplied by the speaker, it has not been possible for the transcript to be checked by speakers and so this portion of the document does not represent a formal record of proceedings. Despite best endeavours by Westminster Forum Projects and its suppliers to ensure accuracy, text based on transcription may contain errors which could alter the intended meaning of any portion of the reported content. Anyone who intends to publicly use or refer to any text based on the transcript should make clear that speakers have not had the opportunity for any corrections, or check first with the speaker in question. If in doubt please contact the forum first.

Contents

<u>About this Publication</u>	3
<u>Agenda</u>	4
<u>Session Chair's opening remarks</u>	
Baroness Jolly , Liberal Democrat Lords Spokesperson for Health (<i>transcript</i>)	6
<u>The Voluntary Scheme for Branded Medicines Pricing and Access - key aims</u>	
Robert Kettell , Deputy Director, Medicines Pricing and Supply, Department of Health and Social Care (<i>transcript</i>)	7
Questions and comments from the floor (<i>transcript</i>)	11
<u>'Industry perspective on the Voluntary Scheme for Branded Medicines Pricing and Access'</u>	
Paul Catchpole , Director of Value and Access, ABPI (<i>transcript</i>)	15
David Watson , Director of Pricing and PPRS, ABPI (<i>transcript</i>)	18
Questions and comments from the floor with Robert Kettell , Deputy Director, Medicines Pricing and Supply, Department of Health and Social Care (<i>transcript</i>)	20
<u>Bringing new products to the market - price control, the impact of the Accelerated Access Collaborative and preparing for Brexit</u>	
Paul Ranson , Consultant, Morgan Lewis (<i>transcript</i>)	24
Keith Jordan , Communications, Policy and Access Director, Roche (<i>transcript</i>)	26
Robert Whitmore , Director, Roboleo & Co (<i>transcript</i>)	28
Bhulesh Vadher , Clinical Director of Pharmacy, Oxford University Hospitals NHS Foundation Trust (<i>transcript</i>)	30
Questions and comments from the floor (<i>transcript</i>)	32
<u>Session Chair's closing remarks</u>	
Baroness Jolly , Liberal Democrat Lords Spokesperson for Health (<i>transcript</i>)	36
<u>Session Chair's opening remarks</u>	
Anne Marie Morris MP , Chair, All-Party Parliamentary Group on Access to Medicines and Medical Devices (<i>transcript</i>)	37
<u>'How research and innovation can shape access to cancer drugs'</u>	
Professor Paul Workman , Chief Executive and President, The Institute of Cancer Research (<i>transcript</i>)	38
<u>Meeting patient choice - and implications for cost</u>	
Nick Medhurst , Head of Policy and Public Affairs, Cystic Fibrosis Trust (<i>transcript</i>)	42
<u>Value-based pricing, reimbursement and supply chains - challenges for industry</u>	
Dr Stuart Dollow , Founder, Vermilion Life Sciences (<i>transcript</i>)	45
<u>Emerging forms of competition - evaluating the uptake of biosimilars</u>	
Professor Mike Hannay , Managing Director, East Midlands Academic Health Science Network (<i>transcript</i>)	49
Questions and comments from the floor (<i>transcript</i>)	53
<u>Next steps in assessing cost effectiveness - priorities for NICE</u>	
Meindert Boysen , Director, Centre for Health Technology Evaluation, NICE (<i>transcript</i>)	60
Questions and comments from the floor (<i>transcript</i>)	63
<u>Session Chair's and Westminster Health Forum closing remarks</u>	
Anne Marie Morris MP , Chair, All-Party Parliamentary Group on Access to Medicines and Medical Devices (<i>transcript</i>)	67
Michael Ryan , Deputy Editor, Westminster Health Forum (<i>transcript</i>)	68
<u>Press Links</u>	69
<u>List of Delegates Registered for Seminar</u>	70
<u>Contributor Biographies</u>	75
<u>About the Core Sponsors of the Westminster Health Forum</u>	78

Please be advised that speakers' PowerPoint presentations are included within the transcript itself, just beneath the relevant speaker's text. Please note that not all speakers are able to grant permission for us to include their slides.

About this Publication

This publication reflects proceedings at the Westminster Health Forum Keynote Seminar: Pharmaceutical pricing and access to medicines held on 25th April 2019. The views expressed in the articles are those of the named authors, not those of the Forum or the sponsors, apart from their own articles.

Although Westminster Health Forum is grateful to all sponsors for the funding on which we depend, participation in events and publications is never conditional on being a sponsor. As well as funding ongoing operations, sponsorship enables the Forum to distribute complimentary copies of publications, and offer complimentary tickets for events, to Government ministers, parliamentarians and officials most involved in policy.

This publication is copyright. Its copying, in whole or in part, is not permitted without the prior written consent of the publishers. However, extracts of the text may be reproduced for academic or review purposes, subject to the conditions of use outlined in the previous page, providing they are accurate, are not used in a misleading context and the author, their organisation and the Westminster Health Forum are acknowledged. We would also appreciate being informed.

Westminster Health Forum

UK Headquarters
4 Bracknell Beeches
Old Bracknell Lane West
Bracknell
Berkshire RG12 7BW

T: 01344 864796

F: 01344 420121

publications@westminsterforumprojects.co.uk

Directors

Peter van Gelder

Chris Whitehouse